To identify patients who developed thyroid dysfunction after CPI to estimate the real-world incidence immune related adverse events using electronic health record (EHR) data
Latest Information Update: 19 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Thyroid dysfunction
- Focus Adverse reactions
Most Recent Events
- 19 Jun 2020 New trial record